AzTrials
AzTrials

Ovarian CancerNCT06253559

Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria

An observational study of Ovarian Cancer, run by Latakia University at 1 site in Syria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Ovarian Cancer
How many people
531 participants
Where
1 siteSyria
Study dates
1 Jan 2017to 24 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: all women with ovarian cancer, with age ≥18 years,who have primary ovarian malignancy and underwent surgical or non-surgical treatment. the data recorded from records of the Departments of Gynecology and Oncology at Tishreen University Hospital in Latakia, Al-Bairouni University Hospital in Damascus, and Ibn Rushd Hospital in Aleppo, which are the 3 major hospitals in Syria that admit and treat patients with ovarian cancer.

Who may be able to join

  • female adult (age ≥18 years)
  • primary ovarian malignancy

Who cannot join

  • less than 18 years old
  • women who have benign tumors or metastatic ovarian cancer.

Trial locations and contacts

1 site in 1 country.

Syria1 site

  • Tishreen University

    Latakia

Other trials in Syria

About this study

Official title: Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War

the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer.

Read the detailed description

Ovarian cancer (OC) is the eighth most common cause of death worldwide, and current studies show that the death numbers caused by it will rise dramatically in the coming years. As the epidemiological features of the cancer may vary, studying these different characteristics can help us improve treatment outcomes and add preventive measures. In addition, giving special attention to these features in developing countries, or countries undergoing crisis, will help us understand the associated risk factors in these regions.

Conditions
Ovarian Cancer
Medical subject headings
Ovarian Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06253559
Study groupRoleWhat they receive
ovarian cancer patientsall ovarian cancer patients that meet the criteria of the study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. age

    the age of patients at the time of diagnosis

    Measured: jan 2017 - july 2021

  2. ovarian cancer grade

    ovarian cancer grades frequency among patients

    Measured: jan 2017 - july 2021

  3. histological type of ovarian cancer

    detect the most common type of ovarian cancer

    Measured: jan 2017 - july 2021

  4. sideness of ovarian cancer

    study the frequency of bilateral or unilateral ovarian cancer

    Measured: jan 2017 - july 2021

  5. Cancer Antigen-125

    Cancer Antigen-125 levels, if they are normal or high in ovarian cancer.

    Measured: jan 2017 - july 2021

  6. Treatment

    detect if the patient underwent surgery or chemotherapy or the both

    Measured: jan 2017 - july 2021

  7. symptoms of ovarian cancer

    detect symptoms of disease at diagnosis time

    Measured: jan 2017 - july 2021

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Feb 2024
  2. Study start1 Jan 2017
  3. Primary completion31 Jul 2021
  4. Study completion24 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
531 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06253559
Sponsor's protocol ID
TishreenU -Ovarian Cancer
Status last verified
Feb 2024
First submitted
2 Feb 2024
Last updated
15 Feb 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: data can be shared upon your request

Publications

  • Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018.

    PubMed 30281663

  • Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjoholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.

    PubMed 27325851

  • Yuan R, Zhang C, Li Q, Ji M, He N. The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis. Gynecol Oncol. 2021 Sep;162(3):778-787. doi: 10.1016/j.ygyno.2021.06.008. Epub 2021 Jun 16.

    PubMed 34140180

  • Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.

    PubMed 29809280

  • Shanmughapriya, S., Senthilkumar, G., Arun, S., Das, B. C., & Natarajaseenivasan, K. (2016). Risk factors for epithelial ovarian carcinoma in India: A case control study in low-incidence population. International Journal of Cancer Research, 12(1), 61-68. https://doi.org/10.3923/IJCR.2016.61.68

  • Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.

    PubMed 28443200

  • Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012 Mar;460(3):237-49. doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10.

    PubMed 22322322

  • Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol. 1991 Oct;43(1):9-23. doi: 10.1016/0090-8258(91)90003-n.

    PubMed 1959794

  • Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019.

    PubMed 31118829

  • Meena RK, Syed NA, Sheikh ZA, Guru FR, Mir MH, Banday SZ, Mp AK, Parveen S, Dar NA, Bhat GM. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022 Nov;8:e2200032. doi: 10.1200/GO.22.00032.

    PubMed 36332174

  • McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7.

    PubMed 21716157

  • Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):98-107.

    PubMed 15668482

  • the World Cancer Research Fund (WCRF), worldwide cancer data., 2020; https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ )

  • Lima MA, Dos Santos L, Turri JA, Nonogaki S, Buim M, Lima JF, de Jesus Viana Pinheiro J, Bueno de Toledo Osorio CA, Soares FA, Freitas VM. Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial Ovarian Cancer. Pathobiology. 2016;83(6):316-26. doi: 10.1159/000446244. Epub 2016 Jul 1.

    PubMed 27359117

  • Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20-37. doi: 10.1634/theoncologist.12-1-20.

    PubMed 17227898

Questions about this trial

What is this clinical trial studying?

An observational study of Ovarian Cancer, run by Latakia University at 1 site in Syria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

age (time frame: jan 2017 - july 2021). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06253559, which also lists 30 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in